NCT06633991

Brief Summary

The aim of the present study is to examine whether the standard treatment prescribed to migraine patients is potentiated when coupled with a verbal instruction inducing more hope and optimism. In order to achieve the goal, outpatients with low-frequency episodic migraine diagnoses (\<8 attacks per month) and outpatients with chronic migraine diagnoses (\>15 attacks per month) will be screened and enrolled, thereafter they will be exposed to verbal instruction inducing more hope and optimism or to verbal instruction inducing hope and optimism together with standard treatment. We hypothesize that the group receiving verbal instruction inducing more hope and optimism would develop larger improvements in all outcome measures.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
102

participants targeted

Target at P50-P75 for not_applicable

Timeline
Completed

Started Jan 2022

Typical duration for not_applicable

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

January 1, 2022

Completed
2 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

December 31, 2023

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

December 31, 2023

Completed
9 months until next milestone

First Submitted

Initial submission to the registry

October 7, 2024

Completed
2 days until next milestone

First Posted

Study publicly available on registry

October 9, 2024

Completed
Last Updated

October 15, 2024

Status Verified

October 1, 2024

Enrollment Period

2 years

First QC Date

October 7, 2024

Last Update Submit

October 9, 2024

Conditions

Keywords

expectationsplacebo effectmigraineverbal instrucitons

Outcome Measures

Primary Outcomes (2)

  • Headache Impact Test

    self-report scale assessing the disability due to migraine

    baseline, 7-day, 15-day, 1- and 3-month follow-ups

  • Intensity of migraine

    A Numeric Rating Scale (NRS) assessing the intensity of migraine pain on a 11-point NRS (0 = no pain, 10 = worst imaginable pain) during the last migraine attack

    baseline, 7-day, 15-day, 1- and 3-month follow-ups

Secondary Outcomes (1)

  • Expectancies

    baseline, 7-day, 15-day, 1- and 3-month follow-ups

Study Arms (2)

instructions inducing hope and optimism

EXPERIMENTAL

The verbal instruction inducing more hope and optimism will be: "The present therapy is a very effective one for your specific type of headache. By taking it, a large number of patients experienced significant pain relieve and improvement in functional capacity

Procedure: verbal instructions

neutral instructions

PLACEBO COMPARATOR

The verbal instruction inducing hope and optimism will be: "The present therapy is an effective one for your specific type of headache. By taking it, a large number of patients experienced pain relieve and improvement in functional capacity".

Procedure: verbal instructions

Interventions

verbal instructions inducing hope and optimism were administered as experimental condition vs neutral instructions (i.e., instructions not able to induce hope and optimism although realistic ones)

Also known as: verbal instrucitons
instructions inducing hope and optimismneutral instructions

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Incident or prevalent diagnosis of low-frequency episodic migraine or chronic migraine according to ICHD criteria version 3 beta 2013.
  • Age of at least 18 years.
  • Signature of informed consent.

You may not qualify if:

  • Standard treatment proposed different from topiramate, amitriptyline, valproate, β-blockers.
  • Inability to understand and want.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Fiammetta COSCI

Florence, 50135, Italy

Location

MeSH Terms

Conditions

Migraine Disorders

Condition Hierarchy (Ancestors)

Headache Disorders, PrimaryHeadache DisordersBrain DiseasesCentral Nervous System DiseasesNervous System Diseases

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
SINGLE
Who Masked
PARTICIPANT
Masking Details
participants did not know whether they were allocated to the control or the experimental condition
Purpose
TREATMENT
Intervention Model
PARALLEL
Model Details: control vs experiemntal condition
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Professor

Study Record Dates

First Submitted

October 7, 2024

First Posted

October 9, 2024

Study Start

January 1, 2022

Primary Completion

December 31, 2023

Study Completion

December 31, 2023

Last Updated

October 15, 2024

Record last verified: 2024-10

Data Sharing

IPD Sharing
Will not share

IPD were made available only to the researchers directly involved in the data collection.

Locations